Literature DB >> 22722789

Activated leukocyte cell-adhesion molecule (ALCAM) promotes malignant phenotypes of malignant mesothelioma.

Futoshi Ishiguro1, Hideki Murakami, Tetsuya Mizuno, Makiko Fujii, Yutaka Kondo, Noriyasu Usami, Kohei Yokoi, Hirotaka Osada, Yoshitaka Sekido.   

Abstract

INTRODUCTION: Cell-adhesion molecules play important roles involving the malignant phenotypes of human cancer cells. However, detailed characteristics of aberrant expression status of cell-adhesion molecules in malignant mesothelioma (MM) cells and their possible biological roles for MM malignancy remain poorly understood.
METHODS: DNA microarray analysis was employed to identify aberrantly expressing genes using 20 MM cell lines. Activated leukocyte cell-adhesion molecule (ALCAM) expression in MM cell lines was analyzed with quantitative reverse transcription-polymerase chain reaction and Western blot analyses in 47 primary MM specimens with immunohistochemistry. ALCAM knockdown in MM cell lines was performed with lentivirus-mediated short hairpin RNA (shRNA) transduction. Purified soluble ALCAM (sALCAM) protein was used for in vitro experiments, whereas MM cell lines infected with the sALCAM-expressing lentivirus were tested for tumorigenicity in vivo.
RESULTS: ALCAM, a member of the immunoglobulin superfamily, was detected as one of the most highly upregulated genes among 103 cell-adhesion molecules with microarray analysis. Elevated expression levels of ALCAM messenger RNA and protein were detected in all 20 cell lines. Positive staining of ALCAM was detected in 26 of 47 MM specimens (55%) with immunohistochemistry. ALCAM knockdown with shRNA suppressed cell migration and invasion of MM cell lines. Purified sALCAM protein impaired the migration and invasion of MM cells in vitro, and the infection of sALCAM-expressing virus into MM cells significantly prolonged survival periods of MM-transplanted nude mice in vivo.
CONCLUSION: Our study suggests that overexpression of ALCAM contributes to tumor progression in MM and that ALCAM might be a potential therapeutic target of MM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722789     DOI: 10.1097/JTO.0b013e31824af2db

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  7 in total

1.  Activated leucocyte cell adhesion molecule (ALCAM/CD166) regulates T cell responses in a murine model of food allergy.

Authors:  Y S Kim; M N Kim; K E Lee; J Y Hong; M S Oh; S Y Kim; K W Kim; M H Sohn
Journal:  Clin Exp Immunol       Date:  2018-02-20       Impact factor: 4.330

2.  Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.

Authors:  Shingo Inaguma; Jerzy Lasota; Zengfeng Wang; Piotr Czapiewski; Renata Langfort; Janusz Rys; Joanna Szpor; Piotr Waloszczyk; Krzysztof Okoń; Wojciech Biernat; Hiroshi Ikeda; David S Schrump; Raffit Hassan; Markku Miettinen
Journal:  Hum Pathol       Date:  2017-08-12       Impact factor: 3.466

3.  KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.

Authors:  Yuen Yee Cheng; Casey M Wright; Michaela B Kirschner; Marissa Williams; Kadir H Sarun; Vladimir Sytnyk; Iryna Leshchynska; J James Edelman; Michael P Vallely; Brian C McCaughan; Sonja Klebe; Nico van Zandwijk; Ruby C Y Lin; Glen Reid
Journal:  Mol Cancer       Date:  2016-06-01       Impact factor: 27.401

4.  Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination.

Authors:  Andrew J Sanders; Sioned Owen; Liam D Morgan; Fiona Ruge; Ross J Collins; Lin Ye; Malcolm D Mason; Wen G Jiang
Journal:  Oncotarget       Date:  2019-10-29

5.  Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion.

Authors:  Takamune Achiha; Noriyuki Kijima; Yoshinori Kodama; Naoki Kagawa; Manabu Kinoshita; Yasunori Fujimoto; Masahiro Nonaka; Junya Fukai; Akihiro Inoue; Namiko Nishida; Takumi Yamanaka; Atsuko Harada; Kanji Mori; Naohiro Tsuyuguchi; Takehiro Uda; Kenichi Ishibashi; Yusuke Tomogane; Daisuke Sakamoto; Tomoko Shofuda; Ema Yoshioka; Daisuke Kanematsu; Masayuki Mano; Betty Luu; Michael D Taylor; Yonehiro Kanemura; Haruhiko Kishima
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

6.  ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium.

Authors:  Justine Münsterberg; Desirée Loreth; Laura Brylka; Stefan Werner; Jana Karbanova; Monja Gandrass; Svenja Schneegans; Katharina Besler; Fabienne Hamester; José Ramon Robador; Alexander Thomas Bauer; Stefan Werner Schneider; Michaela Wrage; Katrin Lamszus; Jakob Matschke; Yogesh Vashist; Güntac Uzunoglu; Stefan Steurer; Andrea Kristina Horst; Leticia Oliveira-Ferrer; Markus Glatzel; Thorsten Schinke; Denis Corbeil; Klaus Pantel; Cecile Maire; Harriet Wikman
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

7.  MiR-148b suppressed non-small cell lung cancer progression via inhibiting ALCAM through the NF-κB signaling pathway.

Authors:  Zhe Jiang; JingWen Zhang; FuHui Chen; Yajiao Sun
Journal:  Thorac Cancer       Date:  2019-12-27       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.